Skip to content

Author

Abby E. Rudolph

5 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Effectiveness of RSV vaccine against cardio-respiratory hospitalizations in heart failure: a prespecified analysis of the DAN-RSV trial

Individuals living with heart failure (HF) are predisposed to severe cardio-respiratory disease (CRD) complications following respiratory syncytial virus (RSV) infection. A bivalent RSV prefusion F protein-based (RSVpreF) vaccine reduced the risk of hospitalization for RSV-related respiratory tract disease (RTD),...

K. Skaarup, M. Lassen, M. Yafasov et al. · 0 citations
Open access Oct 2026

Effect of bivalent RSV prefusion F protein-based vaccine on myocarditis and pericarditis: a prespecified safety analysis of the DAN-RSV trial

Myocarditis and pericarditis are inflammatory cardiac syndromes that have been monitored as outcomes of special interest in adult vaccination programs. Previous randomized and observational studies of RSVpreF vaccination have not identified an association with these events; however, given their low incidence, pri...

M. Yafasov, M. Pareek, M. Lassen et al. · 0 citations
Open access Oct 2026

Effectiveness of a bivalent RSV prefusion F protein-based vaccine in individuals with and without atherosclerotic cardiovascular disease: a prespecified analysis of the DAN-RSV trial

A prespecified analysis of the complete two-season DAN-RSV trial cohort will examine the vaccine effectiveness (VE) of RSVpreF versus no vaccine on respiratory and CV events among participants with or without pre-existing ASCVD.

M. Pareek, M. Lassen, M. Yafasov et al. · 0 citations
Aug 2026

Bivalent RSV Prefusion F Vaccine to Prevent Hospitalizations in Adults.

BACKGROUND Respiratory syncytial virus (RSV) is an important cause of severe respiratory disease in adults, with the highest burden among older adults and individuals with chronic health conditions. The bivalent RSV prefusion F (RSVpreF) vaccine has been shown to prevent RSV-associated respiratory illness, but data fro...

M. Lassen, S. Christensen, M. Yafasov et al. · 1 citation
Open access Jul 2026

Modeling the public health impact of vaccination with Pfizer-BioNTech COVID-19 vaccine, LP.8.1, 2025-2026 formula in the pediatric population aged 5-17 years at high risk of severe outcomes from COVID-19 in the United States.

INTRODUCTION This study evaluated the potential public health impact of receiving Pfizer-BioNTech COVID-19 vaccine, LP.8.1, 2025-2026 formula, in the US pediatric population aged 5-17 years at high risk of severe outcomes from COVID-19. RESEARCH DESIGN AND METHODS A previously published static decision-tree model was...

A. Yehoshua, M. di Fusco, Abby E. Rudolph et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.